Restoration of HOXA4 expression re-sensitises CLL cells to multiple therapeutic agents, identifying a direct role for HOXA4 in control of sensitivity to chemotherapeutic agents with different mechanisms of action [32]. The gene discussed is HOXA4; the disease is B-cell chronic lymphocytic leukemia.